Abstract
The emergence of multi- and extensively-drug resistant strains of Mycobacterium tuberculosis makes the development of novel anti-tubercular compounds and the identification of alternative mycobacterial drugable targets urgent priorities. Recently, type VII secretion systems (T7SS) have been discovered in mycobacteria. The genome of M. tuberculosis encodes 5 of such systems (ESX-1 to - 5), three of which have been characterized and shown to be essential for viability (ESX-3, ESX-5) or virulence (ESX-1, ESX-5). Because of their crucial role in host-pathogen interactions as well as their involvement in basic biological processes of tubercle bacilli, T7SS/ESX represent promising targets for novel anti-tuberculosis drugs. Here, we review the current knowledge of the T7SS/ESX and their impact on M. tuberculosis physiology and virulence. Finally, we discuss the possible approaches to develop T7SS/ESX inhibitors.
Keywords: M. tuberculosis, secretion, virulence, drugs development, tuberculosis.
Current Pharmaceutical Design
Title:Targeting Type VII/ESX Secretion Systems for Development of Novel Antimycobacterial Drugs
Volume: 20 Issue: 27
Author(s): Daria Bottai, Agnese Serafini, Alessandro Cascioferro, Roland Brosch and Riccardo Manganelli
Affiliation:
Keywords: M. tuberculosis, secretion, virulence, drugs development, tuberculosis.
Abstract: The emergence of multi- and extensively-drug resistant strains of Mycobacterium tuberculosis makes the development of novel anti-tubercular compounds and the identification of alternative mycobacterial drugable targets urgent priorities. Recently, type VII secretion systems (T7SS) have been discovered in mycobacteria. The genome of M. tuberculosis encodes 5 of such systems (ESX-1 to - 5), three of which have been characterized and shown to be essential for viability (ESX-3, ESX-5) or virulence (ESX-1, ESX-5). Because of their crucial role in host-pathogen interactions as well as their involvement in basic biological processes of tubercle bacilli, T7SS/ESX represent promising targets for novel anti-tuberculosis drugs. Here, we review the current knowledge of the T7SS/ESX and their impact on M. tuberculosis physiology and virulence. Finally, we discuss the possible approaches to develop T7SS/ESX inhibitors.
Export Options
About this article
Cite this article as:
Bottai Daria, Serafini Agnese, Cascioferro Alessandro, Brosch Roland and Manganelli Riccardo, Targeting Type VII/ESX Secretion Systems for Development of Novel Antimycobacterial Drugs, Current Pharmaceutical Design 2014; 20 (27) . https://dx.doi.org/10.2174/1381612819666131118170717
DOI https://dx.doi.org/10.2174/1381612819666131118170717 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Developments of Indoles as Anti-HIV-1 Inhibitors
Current Pharmaceutical Design The Wide Pharmacological Versatility of Semicarbazones, Thiosemicarbazones and Their Metal Complexes
Mini-Reviews in Medicinal Chemistry Microwave-Assisted Synthesis of Benzo-fused Seven-membered Azaheterocycles
Mini-Reviews in Organic Chemistry Design, Synthesis and Evaluation of Thiourea Derivatives as Antimicrobial and Antiviral Agents
Letters in Drug Design & Discovery Acylhydrazide Schiff Bases: DPPH Radical and Superoxide Anion Scavengers
Medicinal Chemistry Quantification of Rifaximin in Tablets by an Environmentally Friendly Visible Spectrophotometric Method
Current Pharmaceutical Analysis Nanochemistry-Based Immunotherapy for HIV-1
Current Medicinal Chemistry Breath Tests in Diagnosis of Pulmonary Tuberculosis
Recent Patents on Biotechnology Cytokine Status of Serum in Ovarian Cancer Patients with Different Tumor Neoadjuvant Chemotherapy Response
Anti-Cancer Agents in Medicinal Chemistry Interstitial Lung Disease in Idiopathic Inflammatory Myopathy
Current Rheumatology Reviews Biomedical Devices for Pathogen Detection Using Microfluidic Chips
Current Proteomics Formulation and Evaluation of Isoniazid Loaded Nanosponges for Topical Delivery
Pharmaceutical Nanotechnology Phosphoserine Aminotransferase has Conserved Active Site from Microbes to Higher Eukaryotes with Minor Deviations
Protein & Peptide Letters Antibacterial Activities of Flavonoids: Structure-Activity Relationship and Mechanism
Current Medicinal Chemistry Mode of Action of Anti-Infective Agents Focus on Oxidative Stress and Electron Transfer
Current Pharmaceutical Design Synthesis and Enzymological Characterization of Some 2-(Substitutedphenylamino) quinazolin-4(3H)-one Derivatives as Potent α-Glucosidase Inhibitors In Vitro
Letters in Drug Design & Discovery Biographical Sketches of Authors
Current Topics in Medicinal Chemistry Withdrawal Notice: EnzyPha, an Engineered Helper Phage Developed to Overcome Most of the Limitations Regarding Filamentous Phage Titration and ELISA Tests
Protein & Peptide Letters Meet the Editorial Board Member
Current Pharmaceutical Biotechnology Long-term Etanercept Therapy Favors Weight Gain and Ameliorates Cachexia in Rheumatoid Arthritis Patients: Roles of Gut Hormones and Leptin
Current Pharmaceutical Design